| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004359 | American Journal of Ophthalmology | 2009 | 8 Pages |
Abstract
Ranibizumab therapy for CNV secondary to AMD is associated with reduced levels of aqueous VEGF and PEDF regardless of combined therapy with PDT. The reduction levels of VEGF and PEDF are correlated with anatomic improvements in the macula.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jae Kyoun Ahn, Hyung Jin Moon,